Unrecognised myocardial infarction in patients with schizophrenia

Acta Neuropsychiatrica

Volumn 27, Issue 2, 2015, Pages 106-112

  Nielsen, Jimmi ^a,b   Juel, Jacob ^a   Al Zuhairi, Karam Sadoon Majeed ^a   Friis, Rasmus ^a   Graff, Claus ^b   Kanters, Jorgen Kim ^c,d   Jensen, Svend Eggert ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

AMI; mortality; pain perception; psychosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; COMORBIDITY; DENMARK; DIABETES MELLITUS; DISEASE DURATION; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; NOCICEPTION; ONSET AGE; PSYCHOSIS; SCHIZOPHRENIA; SILENT MYOCARDIAL INFARCTION; AGED; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOLOGY; REGISTER; STATISTICAL MODEL;

ADULT; AGED; COMORBIDITY; DENMARK; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; REGISTRIES; SCHIZOPHRENIA;

EID: 84927175707     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2014.41     Document Type: Article

References (38)

1. UGGERBY P, NIELSEN RE, CORRELL CU, NIELSEN J. Characteristics and predictors of long-term institutionalization in patients with schizophrenia. Schizophr Res 2011; 131: 120-126.
2. CORRELL CU, NIELSEN J. Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatrica Scandinavica 2010; 122: 341-344.
3. DE HERT MA, VAN WINKEL R, VAN EYCK D et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87-93.
4. MCEVOY JP, MEYER JM, GOFF DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
5. VANCAMPFORT D, KNAPEN J, PROBST M, SCHEEWE T, REMANS S, DE HERT M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand 2012; 125: 352-362.
6. ROICK C, FRITZ-WIEACKER A, MATSCHINGER H et al. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 268-276.
7. NIELSEN J, GRAFF C, KANTERS JK, TOFT E, TAYLOR D, MEYER JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011; 25: 473-490.
8. NIELSEN J, SKADHEDE S, CORRELL CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010; 35: 1997-2004.
9. NIELSEN J, MUNK-JORGENSEN P, SKADHEDE S, CORRELL CU. Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. J Clin Psychiatry 2011; 72: 140-143.
10. MARDER SR, ESSOCK SM, MILLER AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349.
11. SAHA S, CHANT D, MCGRATH J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-1131.
12. LAURSEN TM, NORDENTOFT M. Heart disease treatment and mortality in schizophrenia and bipolar disorder-changes in the Danish population between 1994 and 2006. J Psychiatr Res 2011; 45: 29-35.
13. KANNEL WB. Silent myocardial ischemia and infarction: insights from the Framingham Study. Cardiol Clin 1986; 4: 583-591.
14. KANNEL WB, ABBOTT RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1984; 311: 1144-1147.
15. SIGURDSSON E, THORGEIRSSON G, SIGVALDASON H, SIGFUSSON N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med 1995; 122: 96-102.
16. VALENSI P, LORGIS L, COTTIN Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis 2011; 104: 178-188.
17. ARENJA N, MUELLER C, EHL NF et al. Prevalence, extent, and independent predictors of silent myocardial infarction. Am J Med 2013; 126: 515-522.
18. NIAKAN E, HARATI Y, ROLAK LA, COMSTOCK JP, ROKEY R. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986; 146: 2229-2230.
19. ROSENTHAL SH, PORTER KA, COFFEY B. Pain insensitivity in schizophrenia. Case report and review of the literature. Gen Hosp Psychiatry 1990; 12: 319-322.
20. APTER JT. The "silent" acute abdomen of schizophrenia. J Med Soc N J 1981; 78: 679-680.
21. FISHBAIN DA. Pain insensitivity in psychosis. Ann Emerg Med 1982; 11: 630-632.
22. HOOLEY JM, DELGADO ML. Pain insensitivity in the relatives of schizophrenia patients. Schizophr Res 2001; 47: 265-273.
23. MARCHAND WE. Occurrence of painless myocardial infarction in psychotic patients. N Engl J Med 1955; 253: 51-55.
24. BONNOT O, ANDERSON GM, COHEN D,WILLER JC, TORDJMAN S. Are patients with schizophrenia insensitive to pain? A reconsideration of the question. Clin J Pain 2009; 25: 244-252.
25. SINGH MK, GILES LL, NASRALLAH HA. Pain insensitivity in schizophrenia: trait or state marker? J Psychiatr Pract 2006; 12: 90-102.
26. MORS O, PERTO GP, MORTENSEN PB. The Danish psychiatric Central Research Register. Scand J Public Health 2011; 39: 54-57.
27. THYGESEN K, ALPERT JS, WHITE HD. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-2538.
28. ANDERSEN TH, KAPPERS D, SNEIDER B, UGGERBY P, NIELSEN J. Involuntary treatment of schizophrenia patients 2004-2010 in Denmark. Acta Psychiatr Scand 2014; 129: 312-319.
29. AMMAR KA, KORS JA, YAWN BP, RODEHEFFER RJ. Defining unrecognized myocardial infarction: a call for standardized electrocardiographic diagnostic criteria. Am Heart J 2004; 148: 277-284.
30. THYGESEN K, ALPERT JS, JAFFE AS, SIMOONS ML, CHAITMAN BR, WHITE HD. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567.
31. RASOUL S, DE BOER MJ, SURYAPRANATA H et al. Circumflex artery-related acute myocardial infarction: limited ECG abnormalities but poor outcome. Neth Heart J 2007; 15: 286-290.
32. YANO K, MACLEAN CJ. The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med 1989; 149: 1528-1532.
33. UGGERBY P, OSTERGAARD SD, ROGE R, CORRELL CU, NIELSEN J. The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Dan Med J 2013; 60: A4578.
34. MADSEN M, DAVIDSEN M, RASMUSSEN S, ABILDSTROM SZ, OSLER M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56: 124-130.
35. NASRALLAH HA, MEYER JM, GOFF DC et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15-22.
36. BURGESS DC, HUNT D, LI L et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2010; 31: 92-99.
37. SCIRICA BM. Prevalence, incidence, and implications of silent myocardial infarctions in patients with diabetes mellitus. Circulation 2013; 127: 965-967.
38. SEJIL S, JANAND-DELENNE B, AVIERINOS JF et al. Six-year follow-up of a cohort of 203 patients with diabetes after screening for silent myocardial ischaemia. Diabet Med 2006; 23: 1186-1191.